Pervasive Sensing and AI in Intelligent ICU
Key facts
- Who runs it
- University of Florida
- Where
- Gainesville, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 400 people, planned
- Started
- 24 May 2021
- Expected to end
- Dec 2026
- Type of study
- Observational
- Treatments tested
- Video Monitoring
- Accelerometer Monitoring
- Noise Level Monitoring
- Light Level Monitoring
- Air Quality Monitoring
- EKG Monitoring
- Vitals Monitoring
- Biosample Collection
- Delirium Motor Subtyping Scale 4 (DMSS-4)
- Record updated
- 6 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (7)Hide the full registry criteria
Who can take part
- aged 18 or older
- admitted to UF Health Shands Gainesville ICU ward
- expected to remain in ICU ward for at least 24 hours at time of screening
Who cannot take part
- under the age of 18
- on any contact/isolation precautions
- expected to transfer or discharge from the ICU in 24 hours or less
- unable to provide self-consent or has no available proxy/LAR
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
This trial is currently available in United States.
- University of Florida Health Shands HospitalGainesville, United StatesContact: Andrea Davidson, BSTaking people
About the trial
What the trial wants to find out
Important information related to the visual assessment of patients, such as facial expressions, head and extremity movements, posture, and mobility are captured sporadically by overburdened nurses, or are not captured at all. Consequently, these important visual cues, although associated with critical indices such as physical functioning, pain, delirious state, and impending clinical deterioration, often cannot be incorporated into clinical status. The overall objectives of this project are to sense, quantify, and communicate patients' clinical conditions in an autonomous and precise manner, and develop a pervasive intelligent sensing system that combines deep learning algorithms with continuous data from inertial, color, and depth image sensors for autonomous visual assessment of critically ill patients. The central hypothesis is that deep learning models will be superior to existing acuity clinical scores by predicting acuity in a dynamic, precise, and interpretable manner, using autonomous assessment of pain, emotional distress, and physical function, together with clinical and physiologic data.
The group in the trial
- adult ICU patients
adult patients aged 18 or older admitted to University of Florida Health Shands Gainesville ICU wards
Treatment: Video Monitoring, Accelerometer Monitoring, Noise Level Monitoring, Light Level Monitoring, Air Quality Monitoring, EKG Monitoring, Vitals Monitoring, Biosample Collection, and Delirium Motor Subtyping Scale 4 (DMSS-4)
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pervasive Sensing and Artificial Intelligence in Intelligent ICU Subtitles: -Intelligent Intensive Care Unit (I2CU): Pervasive Sensing and Artificial Intelligence for Augmented Clinical Decision-making -ADAPT: Autonomous Delirium Monitoring and Adaptive Prevention
- Criteria questions
- Built from NCT05127265, who can take part
- Record updated
- 6 July 2026